Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.1 (
phosphodiesterase
)
18,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Bis(monoacylglycero)phosphate was purified from the livers of chloroquine-treated rats and labeled with tritium by a nonreductive catalytic exchange procedure. The mechanism of its degradation by rat liver lysosomes has been examined. A substantial amount of bis(monoacylglycero)P is degraded to monoglyceride and lysophosphatidic acid by a lysosomal
phosphodiesterase
having an acid pH optimum. Some bis(monoacylglycero)P is degraded to lysophosphatidylglycerol by lysosomal phospholipase A. In contrast, other phosphoglycerides have been reported to be degraded by sequential deacylation in lysosomes. The initial rate of breakdown of bis(monoacylglycero)P is only 10% of the rate observed for dioleoylphosphatidylcholine. [3H]
Lysophosphatidylglycerol
conversion to [3H]bis(monoacylglycero)P is stimulated by unlabeled bis(monoacylglycero)P, resulting in a futile cycle which allows the resynthesis of bis(monoacylglycero)P from its breakdown product, lysophosphatidylglycerol. This futile cycle and the unusual sn-1-glycerophospho-sn-1'-glycerol stereoconfiguration of the water-soluble backbone (Joutti, A., Brotherus, J., Renkonen, O., Laine, R., and Fischer, W. (1976) Biochim. Biophys. Acta 450, 206-209) may be important factors in the marked resistance of bis(monoacylglycero)P to degradation by lysosomal acid hydrolases.
...
PMID:Degradation of bis(monoacylglycero)phosphate by an acid phosphodiesterase in rat liver lysosomes. 3 89